medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2018, Number 07

<< Back Next >>

Ginecol Obstet Mex 2018; 86 (07)

Clinical outcomes in a Colombian cohort of patients with vaginal discharge syndrome treated with antifungals and antibiotics

Castro-Moreno CA, Sánchez-Vanegas G

Language: Spanish
References: 18
Page: 456-463
PDF size: 290.38 Kb.


ABSTRACT

Objective: To know the real life clinical performance of the prescription of two drugs for the treatment of vaginal discharge syndrome (Fluconazole-Secnidazole and Terconazole-Clindamycin) and to compare the clinical outcomes.
Materials and Methods: An analytical cohort study was conducted. We included women older than 18 years with a diagnosis of vaginal discharge syndrome who were candidates to be treated with Fluconazole-Secnidazole or Terconazole-Clindamycin with 8 days (±3) of follow-up, in 12 cities of Colombia. This project was approved by a research with human being’s ethics committee.
Results: 176 patients were included, 153 (86.9%) completed the follow-up, their age ranged between 18 and 67 years. 134 (76.1%) started treatment with Fluconazole- Secnidazole and 42 (23.8%) Terconazole-Clindamycin. Symptoms improvement was compared (Enrollment vs. Control), finding for Fluconazole-Secnidazole and Terconazole- Clindamycin: discharge (p=0.0000), pruritus (p=0.002), irritation (p=0.0000), bad smell (p=0.001) and dyspareunia (p=0.4).
Conclusions: The prescription of the combination Fluconazole-Secnidazole was more frequent. The adherence to treatment was 86%. The proportion of improvement in symptoms ranged between 15% and 40%, however, for the case of vaginal dis- charge it was greater than 70% (Fluconazole-Secnidazole: 115/121 and Terconazole- Clindamycin: 29/41).


REFERENCES

  1. Centros para el Control y la Prevención de Enfermedades (CDC). Vaginosis bacteriana: Hoja informativa de los CDC. EE.UU.2015. [Disponible en: https://www.cdc.gov/std/ spanish/vb/stdfact-bacterial-vaginosis-s.htm.

  2. Mejía-Pérez D, Ángel-Müller E, Rodríguez-Hernández AE, Ruiz-Parra AI, Tolosa-Ardila JE, Gaitán-Duarte H. Características operativas del diagnóstico clínico con y sin pruebas de consultorio (ph y pruebas de aminas) para el diagnóstico de vaginosis bacteriana, en pacientes sintomáticas en Bogotá, Colombia. https://revista.fecolsog.org/index.php/rcog/ article/viewFile/292/310.

  3. Oduyebo OO, Anorlu RI, Ogunsola FT. The effects of antimicrobial therapy on bacterial vaginosis in non-pregnant women. Cochrane Database 2006. DOI: 10.1002/14651858. CD006055.

  4. Vidal E, Ugarte C. Síndrome de flujo vaginal. Revista Cubana de Obstetricia y Ginecología. 2010;36:594-602.

  5. Ministerio de Salud y Protección Social de Colombia, COLCIENCIAS. Guía de práctica clínica para el abordaje sindrómico del diagnóstico y tratamiento de los pacientes con infecciones de transmisión sexual y otras infecciones del tracto genital. Colombia 2013;642.

  6. López J, Ureta E, Uribarren T. Vaginosis bacteriana. México2015 [Available from: http://www.facmed.unam.mx/deptos/ microbiologia/bacteriologia/vaginosis-bacteriana.html.

  7. Villaseca R, Ovalle A, Amaya F, Labra B, Escalona N, Lizana P, et al. Infecciones vaginales en un Centro de Salud Familiar de la Región Metropolitana, Chile. Revista chilena de infectología. 2015;32:30-6. http://dx.doi.org/10.4067/ S0716-10182015000200005

  8. López-Torres L, Chiappe M, Cárcamo C, Garnett G, Holmes K, García P. Prevalencia de vaginosis bacteriana y factores asociados en veinte ciudades del Perú. Revista Peruana de Medicina Experimental y Salud Pública. 2016;33:448-54. https://doi.org/10.17843/rpmesp.2016.333.2350

  9. Koumans EH, Sternberg M, Bruce C, McQuillan G, Kendrick J, Sutton M, et al. The prevalence of bacterial vaginosis in the United States, 2001-2004; associations with symptoms, sexual behaviors, and reproductive health. Sex Transm Dis. 2007;34(11):864-9.

  10. García P. Vaginosis bacteriana. Rev Per Ginecol Obstet,. 2007;53:167-71.

  11. Cardona J, Valencia M, Suárez J, Herrera-Posada D. Prevalencia de vaginosis bacteriana en usuarios de una institución prestadora de servicios de salud de Medellín Colombia. Investigaciones Andina. 2015;17(30):1151-65.

  12. Cauci S, Driussi S, De Santo D, Penacchioni P, Iannicelli T, Lanzafame P, et al. Prevalence of Bacterial Vaginosis and Vaginal Flora Changes in Peri- and Postmenopausal Women. Journal of Clinical Microbiology. 2002;40(6):2147-52.

  13. Martínez Martínez W. Actualización sobre vaginosis bacteriana. Rev Cubana Obstet Ginecol. 2013;39:427-41.

  14. Gaydos CA, Beqaj S, Schwebke JR, Lebed J, Smith B, Davis TE, et al. Clinical Validation of a Test for the Diagnosis of Vaginitis. Obstet Gynecol. 2017;130(1):181-9.

  15. Ferris DG, Litaker MS, Woodward L, Mathis D, Hendrich J. Treatment of bacterial vaginosis: a comparison of oral metronidazole, metronidazole vaginal gel, and clindamycin vaginal cream. J Fam Pract. 1995;41(5):443-9.

  16. Raja IM, Basavareddy A, Mukherjee D, Meher BR. Randomized, double-blind, comparative study of oral metronidazole and tinidazole in treatment of bacterial vaginosis. Indian Journal of Pharmacology. 2016;48(6):654-8.

  17. Villegas Rivera G, López Castellanos K, Casillas Magaña J, Cortés Zárate R, Bishop Montoya E, Romero Medina S, et al. Eficacia y seguridad de clindamicina/clotrimazol, crema vaginal en pacientes mexicanas con cervicovaginitis. Revista mexicana de ciencias farmacéuticas. 2011;42:14-9.

  18. López-Torres L, Chiappe M, Cárcamo C, et al. Prevalencia de vaginosis bacteriana y factores asociados en 20 ciudades del Perú. Rev Peru Med Exp Salud Pública. 2016;33(3):1-7. doi: 10.17843/rpmesp.2016.333.2350




2020     |     www.medigraphic.com